CPA
IPSC icon

Capital Performance Advisors’s Century Therapeutics IPSC Stock Holding History

Capital Performance Advisors’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-12
Closed -$21 – 1381
2024
Q3 		$21 Buy
+12
New +$24 ﹤0.01% 2851

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Performance Advisors's IPSC Position: Q4 2024 in Review

Capital Performance Advisors sold out of Century Therapeutics (IPSC) in Q4 2024, closing a stake of 12 shares — an estimated $21 sold.

Capital Performance Advisors first reported a position in IPSC in Q3 2024 and held it in 1 quarter. The position peaked at $21 in Q3 2024. 72 funds tracked by Wall St. Rank hold IPSC as of Q4 2024.

  • Capital Performance Advisors reported no remaining Century Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 12 Century Therapeutics shares in Q4 2024, an estimated $21.
  • Capital Performance Advisors first reported a position in Century Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Century Therapeutics position peaked at $21 in Q3 2024.
  • 72 funds tracked by Wall St. Rank held Century Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.